Welcome to CSNpharm! For Research Use Only!
Endothelin Receptor
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN13675 | Zibotentan | 186497-07-4 | Zibotentan is an orally administered potent and specific ETA-receptor endothelin A receptor antagonist IC50 21 nM |
| CSN29551 | ZD-1611 | 186497-38-1 | ZD1611 is an endothelin receptor antagonist. |
| CSN12014 | Sulfisoxazole | 127-69-5 | Sulfisoxazole is an antagonist of endothelin receptor that can be used as a sulfonamide antibacterial agent |
| CSN11008 | Ferulic acid sodium | 24276-84-4 | Sodium ferulate is the sodium salt of ferulic acid which is used for the treatment of cardiovascular disease |
| CSN12974 | Sitaxsentan sodium | 210421-74-2 | Sitaxsentan sodium has selectory antagonism of endothelin A ETA receptor with the IC50 and Ki value of 14 nM and 043 nM respectively |
| CSN12975 | Sitaxsentan | 184036-34-8 | Sitaxsentan is a selective endothelin A (ETA) receptor antagonist. |
| CSN24483 | Ro 46-8443 | 175556-12-4 | Ro 46-8443 is the first non-peptide Endothelin Receptor B selective antagonist with IC50 value of 110nM. |
| CSN17902 | Ro 46-2005 | 150725-87-4 | Ro 46-2005 is an antagonist of endothelin receptor |
| CSN18333 | Macitentan (n-butyl analogue) | 556797-16-1 | Macitentan n-butyl analogue is a n-butyl analogue of Macitentan ACT064992 which is an orally active non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis IPF and pulmonary arterial hypertension PAH |
| CSN13736 | Macitentan | 441798-33-0 | Macitentan is an antagonist of endothelin receptor A ETA with IC50 of 05 nM It is developed for treatment of pulmonary arterial hypertension PAH |
| CSN25744 | IRL 2500 | 169545-27-1 | IRL-2500 is a potent endothelin receptor antagonist with IC50 values of 1.3 and 94 nM for ETB and ETA receptors respectively. |
| CSN20320 | HJP272 | 1072467-37-8 | HJP272, an endothelin receptor antagonist, attenuates lipopolysaccharide-induced acute lung injury. |
| CSN23533 | Darusentan | 171714-84-4 | Darusentan is an antagonist of endothelin ETA receptor and it can be used to treat congestive heart failure and hypertension |
| CSN19760 | Clazosentan | 180384-56-9 | Clazosentan is a potent endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury. |
| CSN17348 | BQ-788 sodium salt | 156161-89-6 | BQ-788 sodium salt is a potent selective ETB receptor antagonist with IC50 of 12 nM for inhibition of ET-1 binding to human Girardi heart cells poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM |
| CSN18010 | BQ-788 | 173326-37-9 | BQ-788 is a potent and selective endothelin receptor subtype B ETB antagonist with IC50 of 12 nM inhibits 125I-labeled endothelin 1 ET-1 binding to ETB receptors on human Girardi heart cells |
| CSN10481 | Bosentan (hydrate) | 157212-55-0 | Bosentan is an endothelin (ET) receptor antagonist of ET-A (Ki 4.7 nM) and ET-B (Ki 95 nM). |
| CSN10480 | Bosentan | 147536-97-8 | Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively. |
| CSN25558 | BMS 182874 Hydrochloride | 1215703-04-0 | BMS 182874 Hydrochloride is a potent and selective and competitive non-peptide endothelin ETA receptor antagonist with Ki of 48 nM. |
| CSN12872 | Avosentan | 290815-26-8 | Avosentan is a potent, selective endothelin receptor (ETA receptor) antagonist. |
| CSN18015 | Atrasentan | 173937-91-2 | Atrasentan is an endothelin receptor antagonist (IC500.0551 nM, ETA) being developed for the treatment of prostate cancer. |
| CSN13753 | Atrasentan hydrochloride | 195733-43-8 | Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
| CSN10496 | Ambrisentan | 177036-94-1 | Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor (IC50s 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively). |
| CSN17466 | Aprocitentan | 1103522-45-7 | ACT-132577 is the major and pharmacologically active metabolite of macitentan which is dual ETAETB endothelin ET receptor antagonist designed for tissue targeting |
| CSN28996 | Sparsentan | 254740-64-2 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
